Loading
VeraMorph
VeraMorph is developing VER001, a tablet version of fulvestrant, a hormone-blocking breast cancer drug now given as a monthly injection. It is in laboratory testing.
Also called: VeraMorph, LLCVERAMORPH, LLC
Overview
VeraMorph has an oral drug delivery platform, DPOD, for poorly soluble drugs, and is using it to make oral versions of approved medicines. Its lead product VER001 is an oral formulation of fulvestrant, the selective oestrogen receptor degrader given as a monthly intramuscular injection, for oestrogen receptor-positive metastatic breast cancer. In fiscal year 2026 NCI awarded it USD 935,236 under SBIR award 4R44CA306533-02 for preclinical validation of oral fulvestrant.
Headquarters
Norwood, MA, US
Scorecard
All companies#696of 1706 companies, score 4
- targets +2
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR award (R44) 4R44CA306533-02: Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic breast cancer | 2026 | $935K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1PreclinicalOral selective oestrogen receptor degrader (fulvestrant reformulation)
VER001 is an experimental tablet form of fulvestrant from VeraMorph, for hormone receptor-positive breast cancer that has spread. It is in laboratory testing.
Notes
- The company's claims that its oral fulvestrant is effective are its own and preclinical. Read on veramorph.com and NIH RePORTER on 4 November 2026.
Connected
6Similar pages
- PersonMitch Dowsett
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs).
- TreatmentDiethylstilbestrol
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs).
- TriallidERA
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs).
- TermChemoprevention (tamoxifen, anastrozole, raloxifene) and ER-negative breast cancer
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), Breast cancer (all types).
- TrialevERA
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs).
- TreatmentImlunestrant
Shares Oral SERDs, Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs).
- IdeaLow-dose tamoxifen for high-risk women, prescribed by pharmacists and nurses
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs).
- TreatmentRaloxifene
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs).
cancers
fronts
technologies
targets
drugs
PreclinicalOral selective oestrogen receptor degrader (fulvestrant reformulation)
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
veramorph.com · 2
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/